Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.…
Wall Street Analysts See a 61.23% Upside in Dianthus Therapeutics, Inc. (DNTH): Can the Stock Really Move This High?
Dianthus Therapeutics (NASDAQ: DNTH) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 92 employees.
The shares were at 84.55 USD on 20 November 2026, up 133.0% over 52 weeks. Its 52-week range is 34.29 USD to 117.88 USD: the price is 28.3% below the high and 146.6% above the low.
Its market capitalisation is 4.76B USD.
Dianthus Therapeutics reports return on equity of -32.9% and revenue up 205.6% year over year.
It holds more cash than debt, a net cash position of 836.57M USD. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health. 16 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 139.25 USD is 64.7% above the current price. The next earnings report is expected on 9 March 2027.